MX2009003660A - Farmaco combinado. - Google Patents

Farmaco combinado.

Info

Publication number
MX2009003660A
MX2009003660A MX2009003660A MX2009003660A MX2009003660A MX 2009003660 A MX2009003660 A MX 2009003660A MX 2009003660 A MX2009003660 A MX 2009003660A MX 2009003660 A MX2009003660 A MX 2009003660A MX 2009003660 A MX2009003660 A MX 2009003660A
Authority
MX
Mexico
Prior art keywords
combination drug
agent
combination
provides
present
Prior art date
Application number
MX2009003660A
Other languages
English (en)
Inventor
Yoshikazu Ohta
Toshiya Tamura
Shinji Takagi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2009003660A publication Critical patent/MX2009003660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención provee un agente farmacéutico que contiene un inhibidor de HER2 y un agente terapéutico hormonal o agente anticancerígeno en combinación. La presente invención provee un agente farmacéutico que contiene (1) un inhibidor de HER2 que tiene un esqueleto de pirrolopirimidina o un esqueleto de pirazolopirimidina, y (2) un agente terapéutico hormonal o un agente anticancerígeno en combinación.
MX2009003660A 2006-10-06 2007-10-05 Farmaco combinado. MX2009003660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006275841 2006-10-06
JP2007057902 2007-03-07
PCT/JP2007/070026 WO2008044782A2 (en) 2006-10-06 2007-10-05 Combination drug

Publications (1)

Publication Number Publication Date
MX2009003660A true MX2009003660A (es) 2009-04-22

Family

ID=39283276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003660A MX2009003660A (es) 2006-10-06 2007-10-05 Farmaco combinado.

Country Status (23)

Country Link
US (1) US20100008912A1 (es)
EP (2) EP2359825A2 (es)
JP (1) JP2010505745A (es)
KR (1) KR20090094804A (es)
CN (1) CN101553222A (es)
AR (1) AR063152A1 (es)
AU (1) AU2007307489A1 (es)
BR (1) BRPI0717477A2 (es)
CA (1) CA2665692A1 (es)
CL (1) CL2007002878A1 (es)
CO (1) CO6180429A2 (es)
CR (1) CR10759A (es)
EA (1) EA200970353A1 (es)
EC (1) ECSP099311A (es)
GE (1) GEP20115218B (es)
IL (1) IL197883A0 (es)
MA (1) MA30815B1 (es)
MX (1) MX2009003660A (es)
NO (1) NO20091628L (es)
PE (1) PE20080977A1 (es)
TN (1) TN2009000119A1 (es)
TW (1) TW200823218A (es)
WO (1) WO2008044782A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005250285B2 (en) * 2004-06-02 2011-08-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
KR20100038377A (ko) 2007-06-19 2010-04-14 다케다 야쿠힌 고교 가부시키가이샤 암의 예방／치료제
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2011040212A1 (en) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Therapeutic agent for brain tumor
KR101592258B1 (ko) * 2014-06-20 2016-02-05 보령제약 주식회사 제제 및 이의 제조방법
US10215341B2 (en) * 2016-08-09 2019-02-26 Baker Hughes, A Ge Company, Llc Facilitating the transition between flooding and hydrotesting with the use of an intelligent pig
JP2023518271A (ja) * 2020-03-17 2023-04-28 マイクロベンション インコーポレイテッド 液体塞栓物質

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
JP2006500391A (ja) * 2002-09-04 2006-01-05 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP4366683B2 (ja) 2003-07-28 2009-11-18 武原 力 熱サイホン
AU2005250285B2 (en) * 2004-06-02 2011-08-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
BRPI0511765A (pt) 2004-06-04 2008-01-08 Smithkline Beechman Cork Ltd métodos de tratar cáncer de mama, de pulmão, e colo-retal em um mamìfero
US7745446B2 (en) * 2004-09-06 2010-06-29 Bayer Schering Pharma Aktiengesellschaft Pyrazolo[1,5-c]pyrimidines
JP2006275841A (ja) 2005-03-30 2006-10-12 Taiheiyo Cement Corp セメント中のジエチレングリコール量の定量方法
JP2007057902A (ja) 2005-08-25 2007-03-08 Seiko Epson Corp 画像形成装置

Also Published As

Publication number Publication date
CL2007002878A1 (es) 2008-08-01
PE20080977A1 (es) 2008-09-05
BRPI0717477A2 (pt) 2015-06-16
US20100008912A1 (en) 2010-01-14
TW200823218A (en) 2008-06-01
EP2063895A2 (en) 2009-06-03
CA2665692A1 (en) 2008-04-17
MA30815B1 (fr) 2009-10-01
CO6180429A2 (es) 2010-07-19
CN101553222A (zh) 2009-10-07
NO20091628L (no) 2009-06-26
TN2009000119A1 (en) 2010-10-18
EP2359825A2 (en) 2011-08-24
WO2008044782A3 (en) 2008-12-11
AR063152A1 (es) 2008-12-30
JP2010505745A (ja) 2010-02-25
CR10759A (es) 2009-05-27
GEP20115218B (en) 2011-05-25
AU2007307489A1 (en) 2008-04-17
IL197883A0 (en) 2009-12-24
WO2008044782A2 (en) 2008-04-17
ECSP099311A (es) 2009-06-30
KR20090094804A (ko) 2009-09-08
EA200970353A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
TN2009000119A1 (en) Combination drug
TW200600091A (en) Sulfonylethyl phosphorodiamidates
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
EP2332526A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2006133707A3 (en) Anti-cancer combination treatment and kit-of-part
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
HK1114769A1 (en) Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivative
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
MXPA03001227A (es) Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.
PL1713438T3 (pl) Mydło lecznicze
ZA200701578B (en) Combination anticancer therapy and pharmaceutical compositions therefore
WO2007128588A3 (de) Glutadon
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
RS20050618A (en) Use of dipyridamole in combination with acetylsalicylic acid and an ngiotensin ii antagonist for stroke prevention
WO2005084671A3 (en) Combination of voriconazole and an antifungal cyp2c19 inhibitor
TW200942544A (en) Combination drug
GB0313386D0 (en) Treatment of disease
GEP20104911B (en) Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues
DOP2009000066A (es) Farmaco combinado
EP2027871A4 (en) NEW CATHEPSIN PREPARATION AGAINST CANCER AND THIS USING CANCER FOR COMBINATION THERAPY AGAINST CANCER
UA88468C2 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
WO2007012967A3 (en) Combination of voriconazole and fluconazole

Legal Events

Date Code Title Description
FA Abandonment or withdrawal